Archives of Pharmacal Research

, Volume 27, Issue 2, pp 199–205 | Cite as

Potent inhibition of human cytochrome P450 1 enzymes by dimethoxyphenylvinyl thiophene

  • Sang-Kwang Lee
  • Yongmo Kim
  • Mie Young Kim
  • Sanghee Kim
  • Young-Jin ChunEmail author
Research Articles Articles


Cytochrome P450 (P450) 1 enzymes such as P450 1A1, 1A2, and 1B1 are known to be involved in the oxidative metabolism of various procarcinogens and are regarded as important target enzymes for cancer chemoprevention. Previously, several hydroxystilbene compounds were reported to inhibit P450 1 enzymes and were rated as candidate chemopreventive agents. In this study, we investigated the inhibitory effect of 2-[2-(3,5-dimethoxyphenyl)vinyl]-thiophene (DMPVT), produced from the chemical modification of oxyresveratrol, on the activities of P450 1 enzymes. The inhibitory potential by DMPVT on the P450 1 enzyme activity was evaluated with theEscherichia coli membranes of the recombinant human cytochrome P450 1A1, 1A2, or 1B1 coexpressed with human NADPH-P450 reductase. DMPVT significantly inhibited ethoxyresorufin O-deethylation (EROD) activities with IC50 values of 61, 11, and 2 nM for 1A1, 1A2, and 1B1, respectively. The EROD activity in DMBA-treated rat lung microsomes was also significantly inhibited by DMPVT in a dose-dependent manner. The modes of inhibition by DMPVT were non-competitive for all three P450 enzymes. The inhibition of P450 1B1-mediated EROD activity by DMPVT did not show the irreversible mechanism-based effect. The loss of EROD activity in P450 1B1 with DMPVT incubation was not blocked by treatment with the trapping agents such as glutathione,N-acetylcysteine, or dithiothreitol. Taken together, the results suggested DMPVT to be a strong noncompetitive inhibitor of human P450 1 enzymes that should be considered as a good candidate for a cancer chemopreventive agent in humans.

Key words

Cytochrome P450 1 enzyme Enzyme inhibitor Dimethoxyphenylvinyl thiophene 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., and Mayer, R. T., Ethoxy-, pentoxy- and benzyl-oxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450.Biochem. Pharmacol., 34, 3337–3345 (1985).PubMedCrossRefGoogle Scholar
  2. Cai, Y., Baer-Dubowska, W., Ashwood-Smith, M. J., Ceska, O., Tachibana, S., and DiGiovanni, J., Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins.Chem. Res. Toxicol., 9, 729–736 (1996).PubMedCrossRefGoogle Scholar
  3. Chang, T. K., Lee, W. B., and Ko, H. H.,Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1.Can. J. Physiol. Pharmacol., 78, 874–881 (2000).PubMedCrossRefGoogle Scholar
  4. Cheong, H., Ryu, S. Y., and Kim, K. M., Anti-allergic action of resveratrol and related hydroxystilbenes.Planta Med., 65, 266–268(1999).PubMedCrossRefGoogle Scholar
  5. Chun, Y. J., Kim, M. Y., and Guengerich, F. P., Resveratrol is a selective human cytochrome P450 1A1 inhibitor.Biochem. Biophys. Res. Commun., 262, 20–24 (1999).PubMedCrossRefGoogle Scholar
  6. Chun, Y. J., Kim, S., Kim, D., Lee, S. K., and Guengerich, F. P., A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis.Cancer Res., 61, 8164–8170 (2001a).PubMedGoogle Scholar
  7. Chun, Y. J., Ryu, S. Y., Jeong, T. C., and Kim, M. Y., Mechanismbased inhibition of human cytochrome P450 1A1 by rhapontigenin.Drug Metab. Dispos., 29, 389–393 (2001b).PubMedGoogle Scholar
  8. Ciolino, H. P., Wang, T. T., and Yeh, G. C., Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity.Cancer Res., 58, 2754–2760 (1998).PubMedGoogle Scholar
  9. Ciolino, H. P. and Yeh, G. C., The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor.Br. J. Cancer, 79, 1340–1346 (1999).PubMedCrossRefGoogle Scholar
  10. Dawling, S., Roodi, N., and Pari, F. F., Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1.Cancer Res., 63, 3127–3132 (2003).PubMedGoogle Scholar
  11. Doostdar, H., Burke, M. D., and Mayer, R. T., Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1Aand CYP1B1.Toxicology, 144, 31–38 (2000).PubMedCrossRefGoogle Scholar
  12. Fremont, L., Biological effects of resveratrol.Life Sci., 66, 663–673 (2000).PubMedCrossRefGoogle Scholar
  13. Guengerich, F. P., Analysis and characterization of enzymes, In Hayes, A.W. (Ed). Principles and Methods of Toxicology. Raven Press, New York, pp. 1259–1313, (1994).Google Scholar
  14. Guengerich, F. P., Martin, M. V., Guo, Z., and Chun, Y. J., Purification of functional recombinant P450s from bacteria.Methods Enzymol., 272, 35–44 (1996).PubMedCrossRefGoogle Scholar
  15. Guengerich, F. P. and Shimada, T., Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.Chem. Res. Toxicol., 4, 391–407 (1991).PubMedCrossRefGoogle Scholar
  16. Inouye, K., Saito, A., Orita, M., Tonomura, B., Imaishi, H., and Ohkawa, H., Inhibitory effects of 1,4-naphthoquinone derivatives on rat cytochrome P4501A1-dependent monooxygenase activity in recombinant yeast microsomes.J. Biochem., 127, 1041–1046 (2000).PubMedGoogle Scholar
  17. Jean, P., Lopez-Garcia, P., Dansette, P., Mansuy, D., and Goldstein, J. L., Oxidation of tienilic acid by human yeast- expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.Eur. J. Biochem., 241, 797–804 (1996).PubMedCrossRefGoogle Scholar
  18. Kim, S., Ko, H., Park, J. E., Jung, S., Lee, S. K., and Chun, Y. J., Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.J. Med. Chem., 45, 160–164 (2002a).PubMedCrossRefGoogle Scholar
  19. Kim, Y. M., Yun, J., Lee, C. K., Lee, H., Min, K. R., and Kim, Y., Oxyresveratrol and hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action.J. Biol. Chem., 277, 16340–16344 (2002b).PubMedCrossRefGoogle Scholar
  20. Kleiner, H. E., Vulimiri, S. V., Reed, M. J., Uberecken, A., and DiGiovanni, J., Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation.Chem. Res. Toxicol., 15, 226–235 (2002).PubMedCrossRefGoogle Scholar
  21. Koenigs, L. L., Peter, R. M., Hunter, A. P., Haining, R. L., Rettie, A. E., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F., Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.Biochemistry, 38, 2312–2319 (1999).PubMedCrossRefGoogle Scholar
  22. Mays, D., Hilliard, J., Wong, D., Chambers, M., Park, S., Gelboin, H., and Gerber, N., Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts.J. Pharmacol. Exp. Ther., 254, 720–731 (1990).PubMedGoogle Scholar
  23. Nimmanpisut, S., Chudapongse, P., and Ratanabanangkoon, K., Effects of 2,4,3′,5′-tetrahydroxystilbene on oxidative phosphorylation by rat liver mitochondria.Biochem. Pharmacol., 25, 1245–1248 (1976).PubMedCrossRefGoogle Scholar
  24. Obach, R. S., Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression.J. Pharmacol. Exp. Ther., 294, 88–95 (2000).PubMedGoogle Scholar
  25. O’Donnell, J. P., Dalvie, D. K., Kalgutkar, A. S., and Obach, R. S., Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.Drug Metab. Dispos., 31, 1369–1377 (2003).PubMedCrossRefGoogle Scholar
  26. Omura, T. and Sato, R., The carbon-monoxide binding pigment of liver microsomes.J. Biol. Chem., 239, 2370–2378 (1964).PubMedGoogle Scholar
  27. Parikh, A., Gillam, E. M., and Guengerich, F. P., Drug metabolism byEscherichia coli expressing human cytochromes P450.Nat. Biotechnol., 15, 784–788 (1997).PubMedCrossRefGoogle Scholar
  28. Pervaiz, S., Resveratrol: from grapevines to mammalian biology.FASEB J., 17, 1975–1985 (2003).PubMedCrossRefGoogle Scholar
  29. Schwarz, D., Kisselev, P., and Roots, I., St. John’s wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1.Cancer Res., 63, 8062–8068 (2003).PubMedGoogle Scholar
  30. Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E., Alworth, W. L., and Guengerich, F. P., Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.Chem. Res. Toxicol., 11, 1048–1056 (1998).PubMedCrossRefGoogle Scholar
  31. Shin, N. H., Ryu, S. Y., Choi, E. J., Kang, S. H., Chang, I. M., Min, K. R., and Kim, Y., Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom tyrosinase.Biochem. Biophys. Res. Commun., 243, 801–803 (1998a).PubMedCrossRefGoogle Scholar
  32. Shin, N. H., Ryu, S. Y., Lee, H., Min, K. R., and Kim, Y., Inhibitory effects of hydroxystilbenes on cyclooxygenase from sheep seminal vesicles.Planta Med., 64, 283–284 (1998b).PubMedCrossRefGoogle Scholar
  33. Zhai, S., Dai, R., Friedman, F. K., and Vestal, R. E., Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids.Drug Metab. Dispos., 26, 989–992 (1998).PubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2004

Authors and Affiliations

  • Sang-Kwang Lee
    • 1
  • Yongmo Kim
    • 1
  • Mie Young Kim
    • 1
  • Sanghee Kim
    • 2
  • Young-Jin Chun
    • 1
    Email author
  1. 1.College of PharmacyChung-Ang UniversitySeoulKorea
  2. 2.Natural Products Research Institute, College of PharmacySeoul National UniversitySeoulKorea

Personalised recommendations